Adherence to treatment for tobacco dependence: Association with smoking abstinence and predictors of adherence
Adherence to treatment for tobacco dependence: Association with smoking abstinence and predictors of adherence
复制标题
DOI：
10.1093/ntr/ntq047
复制
发表时间：
2010-06-01
影响因子：
4.7
通讯作者：
Lee, Theodore C.
中科院分区：
文献类型：
--
作者：
Hays, J. Taylor;Leischow, Scott J.;Lee, Theodore C.
在已发表的文献中，对戒烟药物依从性和依从性预测因素的详细分析很少。在这项分析中，我们评估了对烟草依赖治疗的依从性，依从性与戒烟的相关性，以及依从性的预测因素。纳入随机分配至12周治疗组并服用至少1剂指定药物（伐尼克兰[692]、安非他酮缓释剂[669]或安慰剂[684]）的成年吸烟者（N = 2，045）。治疗依从性定义为在12周治疗期内服用≥ 1剂研究药物≥ 80%天数的任何受试者（“完成者”）。在治疗结束时（第9-12周），使用经一氧化碳证实的4周持续戒烟率评估戒烟情况，接受伐尼克兰、安非他酮和安慰剂组的依从率分别为99.3%、98.8%和99.2%。在所有治疗组中，治疗依从性与戒烟率呈正相关。无论是考虑所有受试者还是仅考虑完成者子集，活性治疗与安慰剂相比的治疗效应量（比值比）相似。年龄、每日吸烟量和第2周戒烟是所有治疗组依从性的重要预测因素（所有p <0.05），其中第2周戒烟是最强的预测因素。早期禁欲经验是坚持的强大驱动力。
Detailed analysis of adherence to tobacco cessation medications and predictors of adherence is sparse in published literature. In this analysis, we assessed adherence to tobacco dependence treatment, association of adherence with abstinence, and predictors of adherence.We analyzed pooled results from 2 randomized controlled trials. Adult smokers (N = 2,045) who were randomly assigned to 12 weeks of treatment and took at least 1 dose of the assigned medication (varenicline [692], bupropion sustained release [669], or placebo [684]) were included. Treatment adherence was defined as any subject who took >= 1 dose of study drug for >= 80% days during the 12-week treatment period ("completers"). Smoking abstinence was assessed using carbon monoxide-confirmed 4-week continuous abstinence rate at end of treatment (Weeks 9-12).Adherence rates for completers who received varenicline, bupropion, and placebo groups, respectively, were 99.3%, 98.8%, and 99.2%. There was a positive correlation between adherence to treatment and tobacco abstinence in all treatment groups. Treatment effect sizes (odds ratios) for active therapy compared with placebo were similar whether considering all subjects or only the completer subset. Age, cigarettes per day, and Week-2 abstinence were significant predictors of adherence for all treatment groups (all p < .05), with Week-2 abstinence the strongest predictor.Adherence to pharmacotherapy for smoking cessation is highly correlated with improved tobacco abstinence. Early abstinence experience is a strong driver of adherence.